Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

BACKGROUND: Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb response) and safety of roxadustat in anemic nondialysis-dependent chronic kidney disease (NDD-CKD) subjects. METHODS: NDD-CKD sub...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Nephrol Dial Transplant
Auteurs principaux: Besarab, Anatole, Provenzano, Robert, Hertel, Joachim, Zabaneh, Raja, Klaus, Stephen J., Lee, Tyson, Leong, Robert, Hemmerich, Stefan, Yu, Kin-Hung Peony, Neff, Thomas B.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2015
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4569392/
https://ncbi.nlm.nih.gov/pubmed/26238121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfv302
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires